《大行報告》高盛首予醫脈通(02192.HK)「中性」評級 目標價35元
高盛發表研究報告,首予醫脈通(02192.HK)「中性」評級,目標價35元。該行相信公司作為內地最大線上專業醫師平台,在短期細化市場解決方案需求增加及長遠智能病人管理業務增長支持下,料收入及純利年均複合快速增長可期。該行稱,其專屬科技、內部生成能力,以及策劃社群,料受惠於內地數碼護理市場推廣開支增加。
該行料醫脈通2021至2023年各年收入分別3.6億、6.42億及11.11億元人民幣(下同),每股純利料分別27分、32分及47分。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.